

RESEARCH MONOGRAPH . COMPOUND PROFILE

LPH-5

A conformationally restricted phenethylamine psychedelic developed at Lophora ApS as a highly selective 5-HT_{2A} receptor partial agonist with robust and persistent antidepressant-like activity in rodent models, distinguished from classical psychedelics by pronounced subtype selectivity over the serotonin 5-HT_{2B} and 5-HT_{2C} receptors and currently in Phase 1 clinical evaluation for treatment-resistant depression.

DOCUMENT	KDC-MN-1589
ISSUED	2026-05-20
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	Selective serotonin 5-HT _{2A} receptor partial agonist of the 2,5-dimethoxyphenylpiperidine structural class

ABSTRACT

LPH-5, the (S)-enantiomer of 3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and a conformationally restricted analog of the phenethylamine psychedelic 2C-TFM, is a potent and selective partial agonist of the serotonin 5-hydroxytryptamine type 2A (5-HT_{2A}) receptor under clinical development for treatment-resistant depression and potentially other neuropsychiatric indications. First disclosed in a 2021 patent assigned to Lophora ApS and characterized in the peer-reviewed literature by Marcher-Rorsted et al. (2024) in the Journal of Medicinal Chemistry, LPH-5 emerged from a systematic structure-activity relationship exploration of 2,5-dimethoxyphenylpiperidines in which cyclization of the flexible phenethylamine chain into a piperidine ring, combined with the 4-trifluoromethyl substituent, produced a compound with low-nanomolar 5-HT_{2A} receptor binding affinity (K_i 1.3 nM against [¹²⁵I]DOI), potent functional partial agonism in calcium mobilization assays (EC_{50} 3.2 nM, E_{max} approximately 92 percent of the serotonin maximum at the 5-HT_{2A} receptor), and approximately 60-fold functional selectivity for 5-HT_{2A} over the 5-HT_{2B} receptor, with no measurable agonist activity at the 5-HT_{2C} receptor at concentrations up to 30 micromolar in receptor internalization assays. This selectivity profile distinguishes LPH-5 from classical serotonergic psychedelics such as psilocin, lysergic acid diethylamide, and N,N-dimethyltryptamine, all of which activate the 5-HT_{2B} and 5-HT_{2C} receptors at therapeutically relevant concentrations, and from the parent compound 2C-TFM, which retains substantial 5-HT_{2C} agonist activity.

In preclinical pharmacology, LPH-5 dose-dependently induces the head-twitch response in rodents, a behavioral correlate of 5-HT_{2A} receptor activation and a proxy for psychedelic potential, confirming central target engagement after systemic administration. The compound produces robust acute and persistent antidepressant-like effects in the rat forced swim test, with reduction in immobility observed both at 24 hours and at 7 days after a single administration, a temporal profile consistent with the sustained antidepressant responses reported in clinical trials of psilocybin. The stereochemistry is critical: the (S)-enantiomer (designated the eutomer) is consistently more potent at the 5-HT_{2A} receptor and more selective against the 5-HT_{2C} receptor than the corresponding (R)-distomer across the entire 2,5-dimethoxyphenylpiperidine series. Absolute configuration was confirmed by X-ray crystallography. Physicochemical properties are favorable for central nervous system drug development, with a LogP of 3.45, high membrane permeability (MDR1-MDCKII efflux ratio 0.94), and ligand efficiency metrics (LE 0.6, LLE 5) that position the compound in the optimal drug-like space.

Preclinical toxicology studies completed at Lophora reported no toxicology or histopathology findings, and all chemistry, manufacturing, and controls activities were completed by 2022. The European Medicines Agency authorized a Phase 1 first-in-human clinical trial in September 2024. The trial, a randomized placebo-controlled single- and multiple-ascending-dose study in healthy volunteers conducted at Biotrial in Rennes, France, began dosing subjects in May 2025, with topline results expected in the fourth quarter of 2025. LPH-5 is designed for use in psychedelic-assisted psychotherapy and represents a pharmacological strategy in which the therapeutic benefits of classical psychedelics are

pursued through a compound with improved receptor subtype selectivity, reduced 5-HT_{2B}-associated cardiac risk, and a defined stereochemical identity. This monograph reviews the chemistry, stereochemistry, and structure-activity relationships of LPH-5; the in vitro and in vivo pharmacology at serotonin receptor subtypes; the preclinical behavioral pharmacology; the development history and clinical trajectory; sourcing, reconstitution, and handling considerations for laboratory use; stack interactions; adverse-event expectations; and a structured comparative assessment of five alternative 5-HT_{2A} receptor agonists (psilocybin/psilocin, 25CN-NBOH, DOI, LSD, and the non-hallucinogenic analog tabernanthalog) against LPH-5 on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

Designated Name: LPH-5.

Chemical name (IUPAC): (S)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine.

Alternative names: (S)-2C-TFM-3PIP; (S)-beta,N-trimethylene-2C-TFM. The name LPH-5 is the proprietary designation assigned by Lophora ApS and is the canonical identifier in the development and patent literature. The alternative names relate the compound to the parent phenethylamine 2C-TFM by specifying the piperidine cyclization (3PIP) and the absolute stereochemistry (S) [1].

Chemical Abstracts Service registry number: 2641630-97-7 (free base, S-enantiomer). This CAS number corresponds to the single enantiomer as characterized by Marcher-Rorsted et al. (2024) and confirmed by X-ray crystallography [1].

Development codes: LPH-5 (Lophora ApS). The compound is identified as compound (S)-11 in the Marcher-Rorsted et al. (2024) Journal of Medicinal Chemistry publication [1].

ClinicalTrials.gov identifier: NCT06722820 (Phase 1, first-in-human, healthy volunteers).

Patent: US 2021/0137908, filed May 13, 2021, assigned to Lophora ApS. European and other jurisdictional patents have been granted [2].

1.2 Structural class and chemistry

LPH-5 is a conformationally restricted phenethylamine of the 2,5-dimethoxyphenylpiperidine structural class. It belongs simultaneously to three overlapping chemical families: the 2C family of substituted phenethylamines (defined by the 2,5-dimethoxy substitution pattern on the phenyl ring), the 3-phenylpiperidine family (defined by the saturated six-membered nitrogen heterocycle bearing the aryl group at the 3-position), and the broader serotonergic psychedelic class [1, 3].

The compound is derived from 2C-TFM (2-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)ethan-1-amine) by formal cyclization of the beta-carbon of the ethylamine chain to the nitrogen through a propylene bridge, generating the piperidine ring. This structural modification restricts the conformational flexibility of the ethylamine pharmacophore and is the principal basis for the enhanced 5-HT_{2A}/5-HT_{2C} selectivity relative to the open-chain parent [1].

Molecular formula: C₁₄H₁₈F₃NO₂ (free base).

Molecular weight: 289.30 g/mol (free base, monoisotopic mass 289.1290).

LogP: 3.45 (calculated).

Ligand efficiency: 0.6.

Ligand lipophilicity efficiency: 5.

Physical properties: The compound is supplied as a white to off-white solid. Soluble in dimethyl sulfoxide and in common organic solvents; solubility in aqueous buffer is sufficient for in vitro assay work at the concentrations required for receptor pharmacology.

1.3 Stereochemistry

LPH-5 contains one stereocenter at the C-3 position of the piperidine ring. The active enantiomer is the (S)-configuration, designated the eutomer on the basis of consistently higher potency and selectivity across the 2,5-dimethoxyphenylpiperidine series. The absolute configuration was established by X-ray crystallography of both enantiomers of compound 11 in the Marcher-Rorsted et al. (2024) report [1].

The (R)-distomer is 3- to 13-fold less potent at the 5-HT_{2A} receptor than the (S)-eutomer across the series and, critically, does not display the same selectivity against the 5-HT_{2C} receptor. The enantiomeric differentiation is therefore not merely quantitative (potency) but qualitative (selectivity), making chiral purity essential for the pharmacological profile that defines LPH-5 as a selective 5-HT_{2A} agent [1].

Investigators acquiring research-grade LPH-5 should confirm enantiomeric purity by chiral high-performance liquid chromatography. The compound is supplied as the single (S)-enantiomer by commercial research suppliers.

1.4 Synthesis

The published synthesis of LPH-5 proceeds through the construction of the 3-(2,5-dimethoxyphenyl)piperidine scaffold followed by introduction of the 4-trifluoromethyl group on the aromatic ring. The Marcher-Rorsted et al. (2024) report describes the synthesis of the racemic piperidine and subsequent chiral resolution by preparative chiral HPLC to obtain the individual enantiomers [1]. The absolute configuration was assigned by comparison of the X-ray crystal structures. Final compounds were purified to greater than 95 percent purity by HPLC for pharmacological characterization. Industrial-scale synthesis for clinical supply was completed under GMP conditions by Lophora ApS, with all chemistry, manufacturing, and controls (CMC) activities reported as completed by 2022 [4].

2. Abstract

LPH-5 ((S)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine) is a potent, selective partial agonist of the serotonin 5-HT_{2A} receptor and a serotonergic psychedelic compound under clinical development for treatment-resistant depression. The compound was identified through a systematic structure-activity relationship exploration of 2,5-dimethoxyphenylpiperidines conducted at the University of Copenhagen in collaboration with Lophora ApS, a Danish clinical-stage CNS drug discovery company, and was first described in the peer-reviewed literature by Marcher-Rorsted et al. (2024) [1].

The principal pharmacological distinction of LPH-5 from classical serotonergic psychedelics is receptor subtype selectivity. At the 5-HT_{2A} receptor, LPH-5 binds with a K_i of 1.3 nM and activates the receptor with an EC_{50} of 3.2 nM and an E_{max} of approximately 92 percent of the serotonin maximum in calcium mobilization assays. At the 5-HT_{2B} receptor, functional potency drops approximately 60-fold (EC_{50} 190 nM, E_{max} 65 percent). At the 5-HT_{2C} receptor, LPH-5 shows no measurable agonist activity; instead, it acts as an antagonist (IC_{50} 320 nM). This profile is unique among serotonergic psychedelics: classical agents such as psilocin, LSD, DOI, and N,N-DMT activate both 5-HT_{2A} and 5-HT_{2C} receptors with comparable potency, and several activate the 5-HT_{2B} receptor at concentrations associated with cardiac valvulopathy risk on chronic dosing [1, 5].

In vivo, LPH-5 dose-dependently induces the head-twitch response in rats, confirming central 5-HT_{2A} receptor engagement after systemic administration. A single dose produces robust antidepressant-like effects in the forced swim test at both 24 hours and 7 days after administration, recapitulating the sustained antidepressant profile observed clinically with psilocybin [6]. Preclinical toxicology studies identified no toxicology or histopathology findings [4]. The European Medicines Agency authorized a Phase 1 clinical trial in September 2024; first subjects were dosed at Biotrial in Rennes, France, in May 2025, with topline results anticipated in the fourth quarter of 2025 [7, 8].

LPH-5 occupies a specific position in the psychedelic medicine landscape: it is a defined single-enantiomer synthetic compound with characterized receptor pharmacology, designed for psychedelic-assisted psychotherapy in treatment-resistant

depression. The selectivity for 5-HT_{2A} over 5-HT_{2B} and 5-HT_{2C} addresses two principal concerns with classical psychedelics in chronic or repeated-dose therapeutic paradigms: the cardiac valvulopathy risk associated with 5-HT_{2B} agonism (documented for fenfluramine, ergot derivatives, and other serotonergic agents) and the opposing pharmacological effects of concurrent 5-HT_{2C} activation on mood, appetite, and dopaminergic neurotransmission [1, 9].

3. Discovery and Development History

3.1 Origin and medicinal chemistry campaign

LPH-5 emerged from a medicinal chemistry program at the University of Copenhagen Department of Drug Design and Pharmacology, led by Professor Jesper L. Kristensen, in collaboration with the Latvian Institute of Organic Synthesis in Riga. The program sought to develop selective 5-HT_{2A} receptor agonists from the 2C phenethylamine scaffold by conformational restriction, a classical medicinal chemistry strategy in which the flexible ethylamine side chain is cyclized into a ring system to constrain the bioactive conformation and modulate receptor subtype selectivity [1].

The key insight driving the program was that cyclization of the 2C-type phenethylamine into a piperidine (six-membered ring) produced a striking gain in 5-HT_{2A} versus 5-HT_{2C} selectivity that was not achieved by the corresponding azetidine (four-membered) or pyrrolidine (five-membered) ring homologs. In the calcium mobilization assay, the azetidine (compound 4) was potent at 5-HT_{2A} (EC₅₀ 1.6 nM) but unselective; the pyrrolidine (compound 5eu) showed partial selectivity (EC₅₀ 5.3 nM); and the piperidine (compound 6eu, the 4-bromo analog) achieved functional selectivity with an EC₅₀ of 69 nM [1]. The 4-trifluoromethyl substituent, identified through systematic variation of the 4-position, produced a 20-fold increase in 5-HT_{2A} potency relative to the 4-bromo piperidine while preserving the selectivity, yielding LPH-5 (compound (S)-11) with EC₅₀ 3.2 nM at the 5-HT_{2A} receptor [1].

3.2 Patent and company formation

The compound was covered by patent application US 2021/0137908, filed May 13, 2021, and assigned to Lophora ApS, a Danish clinical-stage CNS drug discovery company founded to advance the LPH series into clinical development. Lophora secured initial funding through grants from the Novo Nordisk Foundation, the Bioinnovation Institute, and Innovation Fund Denmark, and subsequently raised additional capital to fund preclinical and clinical development [2, 4].

3.3 Preclinical development

Lophora initiated formal preclinical development of LPH-5 for treatment-resistant depression and announced completion of all planned preclinical studies in November 2022. The preclinical package included GLP-compliant toxicology and safety pharmacology studies, with the company reporting no toxicology or histopathology findings. All CMC activities for clinical supply were completed by this timepoint [4].

In January 2021, Lophora expanded its advisory board with the addition of Allan Young (Professor of Psychiatry, King's College London), Hartwig Siebner (Professor and Head of Research, Hvidovre Hospital and University of Copenhagen), and Tim Haines (Chairman and Managing Partner, Abingworth) [4].

3.4 Partnership with Beckley Psytech

In May 2022, Beckley Psytech announced a research collaboration and strengthening of relationship with Lophora ApS, bolstering its pipeline of next-generation psychedelic medicines. The collaboration involved joint research on selective 5-HT_{2A} receptor agonists and provided Lophora with access to Beckley Psytech's clinical and regulatory infrastructure [10].

3.5 Regulatory authorization and Phase 1 clinical trial

Lophora submitted a Clinical Trial Authorisation (CTA) application to the French Medicines Agency (ANSM) in June 2024. The European Medicines Agency granted approval to initiate the Phase 1 clinical trial in September 2024 [7]. The trial (NCT06722820) is a randomized, placebo-controlled, single- and multiple-ascending-dose study in healthy volunteers, conducted at Biotrial in Rennes, France, with primary endpoints of safety, tolerability, pharmacokinetics, and pharmacodynamics. First subjects were dosed on or before May 28, 2025. Preliminary data review from the first dosing cohort was scheduled for June 17, 2025, with early clinical data release expected in July 2025 and trial completion targeted for the fourth quarter of 2025 [8].

3.6 Publication of the peer-reviewed characterization

The medicinal chemistry and structure-activity relationship characterization was published in the Journal of Medicinal Chemistry in April 2024 (Marcher-Rorsted et al., J Med Chem 2024; 67(9):7224-7244) [1]. A second publication characterizing the in vivo behavioral pharmacology (head-twitch response, forced swim test, antidepressant-like effects) was published in ACS Pharmacology and Translational Science in May 2025 (Marcher-Rorsted et al., ACS Pharmacol Transl Sci 2025; 8(6):1791-1803) [6].

4. Mechanism of Action

LPH-5 is a selective partial agonist of the serotonin 5-HT_{2A} receptor. Its mechanism of action is defined by three pharmacological properties: high-affinity binding and potent functional activation at the 5-HT_{2A} receptor; markedly reduced functional activity at the 5-HT_{2B} receptor; and absence of agonist activity at the 5-HT_{2C} receptor.

4.1 5-HT_{2A} receptor partial agonism

The 5-HT_{2A} receptor is a G-protein-coupled receptor of the class A (rhodopsin-like) family, coupled primarily to G_q/11 and signaling through phospholipase C, inositol trisphosphate (IP₃), diacylglycerol, and intracellular calcium release. It is expressed at high density on layer V pyramidal neurons of the prefrontal cortex, on claustrum neurons, and at lower density throughout the cortex, hippocampus, amygdala, and thalamus. The 5-HT_{2A} receptor is the principal molecular target mediating the psychedelic effects of classical serotonergic psychedelics (psilocin, LSD, mescaline, DMT, DOI) and is the receptor whose activation correlates with antidepressant efficacy in clinical trials of psilocybin [5, 11].

LPH-5 binds the 5-HT_{2A} receptor with a K_i of 1.3 nM as determined by competition binding against [¹²⁵I]DOI in membranes from HEK293 cells stably expressing the human 5-HT_{2A} receptor [1]. In the functional calcium mobilization (Fluo-4) assay, LPH-5 activates the 5-HT_{2A} receptor with an EC₅₀ of 3.2 nM and an E_{max} of approximately 92 percent of the serotonin maximum, classifying it as a high-efficacy partial agonist [1]. The compound is among the most potent synthetic 5-HT_{2A} agonists reported in the literature, with binding affinity comparable to 25CN-NBOH (K_i 1.3 nM) and exceeding psilocin (K_i approximately 120 to 170 nM) by approximately two orders of magnitude [1, 12].

Downstream signaling through the 5-HT_{2A} receptor includes G_q-mediated phospholipase C activation, IP₁ accumulation, beta-arrestin 2 recruitment, and receptor internalization. The Marcher-Rorsted et al. (2024) report demonstrated that LPH-5 is an efficacious agonist for the induction of 5-HT_{2A} receptor internalization, consistent with the capacity for sustained receptor engagement and the potential for tachyphylaxis on repeated dosing [1].

4.2 5-HT2B receptor selectivity

The 5-HT2B receptor is expressed on cardiac valvular interstitial cells, vascular smooth muscle, pulmonary artery endothelium, and enteric neurons. Chronic activation of the 5-HT2B receptor on cardiac valvular cells induces mitogenic signaling, collagen deposition, and valvular thickening, the pathological mechanism underlying fenfluramine-associated cardiac valvulopathy and ergotamine-associated fibrotic valvular disease [9]. The 5-HT2B receptor is therefore the principal safety-relevant off-target for serotonergic psychedelics under development for chronic or repeated-dose therapeutic applications.

LPH-5 binds the 5-HT2B receptor with a K_i of 13 nM, representing 10-fold lower binding affinity than at the 5-HT2A receptor [1]. Functionally, the selectivity is more pronounced: in the calcium mobilization assay, the 5-HT2B EC_{50} is 190 nM (approximately 60-fold less potent than the 5-HT2A EC_{50} of 3.2 nM) with an E_{max} of 65 percent. At concentrations sufficient for full 5-HT2A receptor activation, 5-HT2B receptor occupancy and activation are predicted to be minimal [1].

4.3 5-HT2C receptor selectivity

The 5-HT2C receptor is expressed on GABAergic interneurons in the ventral tegmental area, on choroid plexus epithelium, and in multiple cortical and limbic regions. Activation of the 5-HT2C receptor produces effects that are in some respects pharmacologically antagonistic to 5-HT2A activation: 5-HT2C agonism reduces mesolimbic dopamine release, suppresses food intake, and can produce anxiogenic effects. In the context of psychedelic-assisted therapy, concurrent 5-HT2C activation may attenuate the rewarding and pro-social components of the psychedelic experience and may contribute to dysphoric responses [13].

LPH-5 binds the 5-HT2C receptor with a K_i of 13 nM [1]. However, at the functional level, the compound shows no measurable agonist activity at the 5-HT2C receptor; it did not induce significant 5-HT2C receptor internalization at concentrations up to 30 micromolar. Instead, LPH-5 acts as an antagonist at the 5-HT2C receptor with an IC_{50} of 320 nM [1]. This functional profile (binding without activation) is the pharmacological basis for the selectivity claim: LPH-5 occupies the 5-HT2C receptor orthosteric site without triggering the downstream Gq signaling cascade, effectively producing a functional blockade of the receptor at higher concentrations.

The mechanistic basis for this dissociation between binding affinity and functional efficacy at the 5-HT_{2C} receptor lies in the conformational restriction imposed by the piperidine ring. The six-membered ring constrains the pharmacophore into a geometry that is competent for orthosteric binding but does not stabilize the active-state conformation of the 5-HT_{2C} receptor with sufficient efficacy to trigger downstream signaling. This conformational selectivity mechanism is the principal pharmacological innovation of the 2,5-dimethoxyphenylpiperidine class [1].

4.4 Broad receptor selectivity

In a broad receptor selectivity screen, LPH-5 exhibited binding affinities at non-serotonergic targets in the high nanomolar (greater than 100 nM) or micromolar ranges, indicating that selective 5-HT_{2A} receptor activation is achievable at appropriate dosing and exposure levels without significant off-target pharmacology [1].

4.5 Structure-activity relationships informing mechanism

The SAR data from the Marcher-Rorsted et al. (2024) report provide mechanistic context for the LPH-5 pharmacological profile:

The 4-position substituent is critical. The trifluoromethyl group produces 20-fold greater 5-HT_{2A} potency than the corresponding 4-bromo, 4-chloro, or 4-iodo analogs. Alkyl substituents (methyl, ethyl, n-butyl) at the 4-position reduce 5-HT_{2A} potency and, importantly, restore 5-HT_{2C} agonist activity that is absent with the halogen and trifluoromethyl substituents [1].

The 2,5-dimethoxy substitution pattern is essential. Removal of the 2-methoxy group produces a greater than 500-fold loss in 5-HT_{2A} potency; removal of the 5-methoxy produces approximately 20-fold loss. Ethylation of either methoxy group reduces potency and restores 5-HT_{2C} agonism [1].

N-alkylation (N-methyl, N-ethyl) substantially reduces potency, consistent with prior work by Glennon showing approximately 10-fold affinity reduction with N-methylation of 2C-type phenethylamines [1].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption and brain penetration

Detailed human pharmacokinetic parameters for LPH-5 have not been published as of the date of this monograph; the Phase 1 clinical trial includes pharmacokinetic endpoints and results are expected in Q4 2025 [8].

Preclinical data support adequate oral absorption and central nervous system penetration. The head-twitch response, a centrally mediated behavioral correlate of 5-HT_{2A} receptor activation, is dose-dependently induced by systemic (intraperitoneal and, in later studies, oral) administration of LPH-5 in rats, confirming that the compound crosses the blood-brain barrier at pharmacologically active concentrations after peripheral administration [6].

Membrane permeability is high. The MDR1-MDCKII bidirectional permeability assay produced an efflux ratio of 0.94, indicating that the compound is not a substrate for P-glycoprotein-mediated efflux at the blood-brain barrier and predicting favorable central nervous system exposure relative to plasma concentrations [1].

5.2 Distribution

Volume of distribution has not been reported in published form. The LogP of 3.45 and the high membrane permeability predict moderate tissue partitioning. The compound is expected to distribute into central nervous system tissue at concentrations consistent with the observed behavioral pharmacology.

5.3 Metabolism

Specific metabolic pathways for LPH-5 have not been characterized in published form. The 2,5-dimethoxy groups on the phenyl ring are predicted sites for O-demethylation by hepatic cytochrome P450 enzymes (particularly CYP2D6 and CYP3A4, based on the metabolism of structurally related 2C-type phenethyl-

lamines). The piperidine nitrogen is a potential site for N-oxidation or N-dealkylation. The trifluoromethyl group is metabolically stable and is not expected to undergo biotransformation at therapeutic concentrations.

The related compound 2C-TFM is metabolized by CYP2D6-mediated O-demethylation, suggesting that CYP2D6 polymorphism may influence the pharmacokinetics of LPH-5. This prediction requires confirmation from the Phase 1 clinical pharmacokinetic data.

5.4 Elimination

Elimination parameters have not been published. Based on structural analogy to other 2C-type phenethylamines, the compound is expected to undergo predominantly hepatic metabolism with renal excretion of conjugated metabolites.

5.5 Routes of administration

The clinical development program is evaluating oral administration. Preclinical studies have used intraperitoneal administration in rats. The compound is amenable to oral dosing on the basis of its physicochemical properties (molecular weight 289, LogP 3.45, favorable membrane permeability) [1, 6].

5.6 Duration of action

LPH-5 is described as having a duration of action consistent with classical psychedelic experiences (hours). The related analog LPH-48, in preclinical development at Lophora for alcoholism, is described as a shorter-acting direct analog of LPH-5, implying that LPH-5 has a longer duration than would be optimal for some therapeutic contexts [14]. Precise duration data from human subjects will emerge from the Phase 1 trial.

6. Preclinical Pharmacology

6.1 Head-twitch response

The head-twitch response (HTR) is a rapid, rhythmic, paroxysmal side-to-side head movement in rodents that is the most pharmacologically specific behavioral correlate of 5-HT_{2A} receptor agonism. The HTR is blocked by selective 5-HT_{2A} antagonists (M100907/volinanserin, ketanserin) and is absent in 5-HT_{2A} receptor knockout mice. The HTR is used as a read-out of in vivo 5-HT_{2A} receptor engagement and as a proxy for psychedelic potential in compound screening.

LPH-5 dose-dependently induced the head-twitch response in rats following systemic administration. The dose-response relationship was consistent with the in vitro potency at the 5-HT_{2A} receptor and confirmed that the compound achieves pharmacologically active central nervous system concentrations after peripheral dosing [6].

6.2 Antidepressant-like behavioral effects

The forced swim test (FST), a widely used rodent behavioral model for antidepressant-like activity, measures immobility time as a proxy for behavioral despair. Classical antidepressants reduce immobility when administered acutely, and psychedelic 5-HT_{2A} agonists (psilocybin, DOI) produce both acute and sustained reductions in immobility that persist for days to weeks after a single administration.

LPH-5 produced robust antidepressant-like effects in the rat FST. Immobility was significantly reduced at 24 hours after a single administration. Critically, the antidepressant-like effect persisted at 7 days after a single dose, recapitulating the sustained efficacy profile that has been the principal clinical observation driving the development of psilocybin for treatment-resistant depression [6]. This temporal persistence is consistent with the hypothesis that 5-HT_{2A} receptor activation triggers downstream neuroplastic changes (including BDNF upregulation, dendritic spine formation, and prefrontal cortical circuit remodeling) that outlast the acute pharmacological effect.

6.3 Receptor internalization and desensitization

LPH-5 efficiently induced 5-HT_{2A} receptor internalization in vitro, whereas it did not induce significant 5-HT_{2C} receptor internalization at concentrations up to 30 micromolar [1]. The selective internalization profile supports the selectivity claim at the cellular level and suggests that repeated dosing would produce tachyphylaxis at the 5-HT_{2A} receptor (consistent with the rapid tolerance observed with classical psychedelics) without compensatory changes at the 5-HT_{2C} receptor.

6.4 Toxicology

Formal preclinical toxicology studies conducted under GLP-compliant conditions at Lophora reported no toxicology or histopathology findings [4]. Specific endpoints (genotoxicity, cardiovascular safety pharmacology, respiratory safety pharmacology, reproductive toxicology) have not been detailed in public disclosures but are implied by the regulatory authorization to proceed to first-in-human dosing.

7. Clinical Evidence Base

7.1 Phase 1 clinical trial

The Phase 1 clinical trial of LPH-5 (NCT06722820) is a randomized, placebo-controlled, single- and multiple-ascending-dose study in healthy volunteers. The study is conducted at Biotrial, a contract research organization in Rennes, France. Primary endpoints are safety, tolerability, pharmacokinetics, and pharmacodynamics. First subjects were dosed on or before May 28, 2025 [8].

Preliminary data review from the first dosing cohort was scheduled for June 17, 2025. Early clinical data release was anticipated for July 2025. Lophora projected completion of the Phase 1 trial in Q4 2025, with topline results guiding further development in treatment-resistant depression and other neuropsychiatric indications [8].

7.2 Anticipated clinical development pathway

LPH-5 is positioned for development in psychedelic-assisted psychotherapy for treatment-resistant depression. The clinical paradigm for psychedelic medicines in this indication involves administration of the psychedelic compound in one to three supervised dosing sessions, with preparatory and integrative psychotherapy sessions before and after each dosing session. This paradigm has been established by the COMP360 psilocybin program (Compass Pathways), which achieved its primary endpoint in two Phase 3 trials for treatment-resistant depression (COMP005, June 2025; COMP006, February 2026) and is pursuing a rolling New Drug Application with the FDA, with a potential approval decision by late 2026 or early 2027 [15].

The clinical development pathway for LPH-5 is expected to follow a similar trajectory: Phase 1 safety and pharmacokinetics in healthy volunteers; Phase 2 proof-of-concept in treatment-resistant depression with psychotherapy accompaniment; and Phase 3 registration trials if Phase 2 signals are positive. The differentiation claim relative to psilocybin is the improved receptor subtype selectivity (reduced 5-HT_{2B} cardiac risk, absence of 5-HT_{2C} agonism) and the defined single-enantiomer synthetic identity.

7.3 Current clinical evidence limitations

As of the date of this monograph (May 2026), no efficacy data in human patients have been published or reported. The compound has demonstrated pharmacological activity only in preclinical rodent models (head-twitch response, forced swim test) and in vitro assay systems. The clinical evidence base is limited to the ongoing Phase 1 healthy volunteer safety and pharmacokinetic study. All statements regarding therapeutic potential are extrapolated from preclinical data and from the clinical evidence for the broader class of 5-HT_{2A} receptor agonists.

8. Sourcing and Quality Verification

Research-grade LPH-5 is available from specialized chemical and pharmacological research suppliers. MedChemExpress lists LPH-5 as a catalog compound for research use [16]. Additional suppliers in the psychedelic and serotonergic research chemical space may carry the compound.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 95 percent (the standard applied by Marcher-Rorsted et al. in the characterization study)
- Mass spectrometry confirmation of molecular weight (expected $[M+H]^+$ 290.14 for the protonated free base)
- Chiral HPLC confirmation of enantiomeric purity (greater than 99 percent enantiomeric excess of the (S)-enantiomer); enantiomeric purity is critical because the (R)-diastomer has a different selectivity profile
- Nuclear magnetic resonance spectroscopy (1H and ^{19}F NMR; the trifluoromethyl group provides a diagnostic ^{19}F signal)
- Residual solvent analysis if the synthesis route is unknown

Third-party analytical confirmation is recommended for any investigation where dose-response precision or mechanism-of-action specificity depends on the selectivity profile, since the (R)-enantiomer restores 5-HT_{2C} agonism that is absent in the (S)-enantiomer.

Pharmaceutical-grade LPH-5 for clinical research is manufactured by Lophora ApS and is not commercially available outside the clinical trial program.

9. Reconstitution and Handling

LPH-5 free base is a solid at room temperature. For in vitro pharmacology, the compound is typically dissolved in dimethyl sulfoxide (DMSO) to prepare concentrated stock solutions (10 to 100 mM), which are then diluted into assay buffer at the required concentrations. Final DMSO concentration in the assay should not exceed 0.1 percent to avoid solvent artifacts.

For in vivo administration in rodent studies, the compound has been administered intraperitoneally in saline or in saline with a small percentage of DMSO or cyclodextrin as a solubilizing agent. Oral administration in formulated preparations is used in the clinical program; formulation details have not been disclosed.

Storage of the solid compound at minus 20 degrees Celsius under desiccation is appropriate for long-term stability. DMSO stock solutions should be stored at minus 20 degrees Celsius, protected from moisture, and used within 3 months of preparation. Repeated freeze-thaw cycles should be minimized; aliquoting of stock solutions for single-use is recommended.

The compound does not require special light protection based on its structural class, though storage in amber vials is reasonable precautionary practice.

10. Stack Interactions and Combinations

LPH-5 interacts with several drug classes through its 5-HT_{2A} receptor pharmacology and its predicted CYP-mediated metabolism. Investigators conducting research with LPH-5, especially in combination with other serotonergic or psychoactive compounds, should consider:

Serotonin reuptake inhibitors (SSRIs, SNRIs): Chronic SSRI therapy downregulates 5-HT_{2A} receptor density through sustained elevation of synaptic serotonin. This downregulation is the likely mechanism by which chronic SSRI use attenuates the subjective effects of psilocybin and other 5-HT_{2A} agonists in human subjects. Concurrent SSRI therapy is expected to reduce the pharmacodynamic effect of LPH-5. Clinical trials of psilocybin typically require SSRI washout before dosing; the same requirement is expected for LPH-5 [17].

5-HT_{2A} receptor antagonists: Concurrent administration of ketanserin, volanserin (M100907), risperidone, or other agents with 5-HT_{2A} antagonist properties will attenuate or abolish the pharmacological effect of LPH-5. This interaction is pharmacologically definitive and is the basis for the use of ketanserin as a rescue agent in psychedelic-assisted therapy sessions.

CYP2D6 inhibitors: By analogy with the metabolism of structurally related 2C-type phenethylamines, strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) may elevate LPH-5 plasma concentrations and prolong duration of effect. This interaction requires confirmation from the Phase 1 pharmacokinetic data.

Monoamine oxidase inhibitors (MAOIs): MAOIs prevent the oxidative deamination of monoamines and can potentiate the effects of serotonergic psychedelics through elevation of synaptic serotonin. The combination of an MAOI with a 5-HT_{2A} agonist carries the risk of serotonin syndrome and is contraindicated.

Other serotonergic psychedelics: Concurrent administration with psilocybin, LSD, DMT, or other 5-HT_{2A} agonists is pharmacologically additive and is not recommended outside of defined pharmacological research protocols.

Lithium: Anecdotal reports and case series suggest that lithium may potentiate the effects of serotonergic psychedelics and increase the risk of seizures. The combination should be avoided.

Cannabis and cannabinoids: The interaction between cannabinoids and serotonergic psychedelics is poorly characterized but anecdotally associated with potentiation of the psychedelic experience. Mechanistic basis is unclear; the interaction does not appear to be pharmacokinetic.

11. Adverse Events and Safety

11.1 Expected adverse events based on mechanism

The adverse-event profile of LPH-5 in humans has not been characterized in published form. Based on the 5-HT_{2A} receptor agonist mechanism and the experience with structurally and mechanistically related compounds, the following adverse events are expected:

Psychedelic effects: Altered perception, visual distortion, synesthesia, emotional lability, and altered sense of time. These are the intended pharmacological effects in the context of psychedelic-assisted therapy and are managed through the therapeutic setting (controlled environment, trained facilitators, preparatory psychotherapy).

Cardiovascular: Modest increases in heart rate and blood pressure are reported with classical 5-HT_{2A} agonists (psilocybin, LSD). The LPH-5 selectivity against the 5-HT_{2B} receptor is expected to mitigate the cardiac valvulopathy risk associated with chronic 5-HT_{2B} agonism, though this advantage is relevant primarily in repeated-dose paradigms.

Gastrointestinal: Nausea is common with classical psychedelics, attributed in part to peripheral 5-HT receptor activation. The selectivity of LPH-5 for the 5-HT_{2A} receptor over other serotonin receptor subtypes may reduce gastrointestinal adverse events relative to psilocybin, but this prediction requires clinical confirmation.

Headache: Reported with psilocybin and other 5-HT_{2A} agonists, likely related to vascular 5-HT receptor activation.

Anxiety and psychological distress: Acute anxiety, paranoia, and dysphoria ("challenging experiences") are reported in a minority of subjects receiving psilocybin. The absence of 5-HT_{2C} agonism in LPH-5 may reduce the frequency or intensity of dysphoric responses, since 5-HT_{2C} activation opposes dopaminergic signaling and is associated with anxiety-like behavior in preclinical models [13]. This mechanistic hypothesis requires clinical verification.

11.2 Preclinical safety

Preclinical toxicology studies at Lophora identified no toxicology or histopathology findings [4]. The absence of 5-HT_{2B} agonism at therapeutically relevant concentrations predicts a favorable cardiac safety profile in preclinical cardiovascular safety pharmacology studies.

11.3 Abuse potential

LPH-5 is a serotonergic psychedelic with hallucinogenic properties. Classical psychedelics have low abuse potential relative to stimulants, opioids, and sedatives: they produce rapid tolerance (tachyphylaxis through 5-HT_{2A} receptor internalization and downregulation), are not associated with compulsive drug-seeking behavior, and are not self-administered by animals in standard abuse-liability paradigms. LPH-5 is expected to have a similar abuse-liability profile. The compound is not explicitly scheduled in the United States or Canada but could be considered a controlled substance under analog legislation if intended for human consumption [3].

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five 5-HT_{2A} receptor agonists against LPH-5, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile (clinical or predicted), and overall validation. The five comparators were selected as the principal 5-HT_{2A} agonists with substantive clinical evidence or pharmacological research programs relevant to the antidepressant and psychedelic-assisted therapy applications.

12.1 Psilocybin/Psilocin

Mechanism: Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a prodrug that is dephosphorylated in vivo to psilocin (4-hydroxy-N,N-dimethyltryptamine), the active metabolite. Psilocin is a non-selective serotonin receptor agonist with comparable affinity for the 5-HT_{2A} (K_i approximately 120 to 170 nM), 5-HT_{2C} (K_i approximately 80 to 310 nM), and 5-HT_{1A} (K_i approximately 150 nM) receptors, and additional activity at 5-HT_{2B} and other serotonin subtypes [18, 19].

Development trajectory: Psilocybin is the most clinically advanced psychedelic compound. Compass Pathways' COMP360 formulation achieved the primary endpoint in both Phase 3 trials for treatment-resistant depression (COMP005, June 2025; COMP006, February 2026) and is pursuing a rolling NDA with the FDA, with potential approval by late 2026 or early 2027 [15]. Usona Institute holds a separate FDA Breakthrough Therapy Designation for psilocybin in major depressive disorder, with a Phase 3 trial (NCT06308653) ongoing.

Novelty: Low. Psilocybin is a naturally occurring tryptamine whose psychoactive properties have been known since the 1950s. The clinical development is a rediscovery rather than a novel pharmacological innovation.

Effect size: Large. The COMP360 Phase 3 trials demonstrated statistically significant and clinically meaningful reduction in MADRS depression scores at 6 weeks in treatment-resistant depression patients after a single 25 mg dose [15]. Open-label

and Phase 2 studies consistently show effect sizes (Cohen's d) in the range of 0.8 to 1.5 on depression rating scales.

Promising potential: Very high. On track for potential FDA approval in 2026 to 2027.

Side-effect profile: The principal adverse events are psychedelic effects (managed in the therapeutic setting), nausea, headache, transient anxiety, and modest cardiovascular changes. The cardiac valvulopathy concern from 5-HT_{2B} agonism is theoretical in the single-dose paradigm but would become relevant in repeated-dose applications. The non-selective receptor profile contributes to the gastrointestinal and dysphoric adverse events.

Overall validation: Very high. The most clinically validated 5-HT_{2A} agonist for antidepressant applications.

Comparison to LPH-5: Psilocin has approximately 100-fold lower binding affinity at the 5-HT_{2A} receptor than LPH-5 and activates 5-HT_{2B} and 5-HT_{2C} receptors at comparable concentrations, which LPH-5 does not. LPH-5 has the theoretical advantages of defined single-enantiomer identity, high subtype selectivity, and reduced cardiac and dysphoric risk, but has no clinical efficacy data. Psilocybin's clinical validation is overwhelming by comparison.

12.2 25CN-NBOH

Mechanism: 25CN-NBOH (2-(4-cyano-2,5-dimethoxyphenyl)-N-(2-hydroxybenzyl)ethanamine) is a highly selective 5-HT_{2A} receptor agonist with K_i of approximately 1.3 nM and EC₅₀ of approximately 2.1 nM, comparable to LPH-5 [12]. It is an N-benzyl phenethylamine (NBOMe/NBOH series derivative) designed as a pharmacological tool compound for selective 5-HT_{2A} receptor investigation.

Development trajectory: 25CN-NBOH is principally a research tool compound. It has been used extensively in preclinical studies to dissect the contribution of 5-HT_{2A} receptor activation to psychedelic-like behavioral effects, cognitive flexibility, and cortical neuron excitability. It has not entered clinical development for any therapeutic indication and is not being advanced by any company for regulatory approval.

Novelty: Moderate. The compound represents the N-benzyl phenethylamine approach to 5-HT_{2A} selectivity, mechanistically distinct from the piperidine cyclization strategy of LPH-5.

Effect size: Preclinical only. The compound induces head-twitch responses, reduces marble burying (anxiety-related behavior), and modulates prefrontal cortical neuron firing in rodent models. No clinical effect-size data exist.

Promising potential: Low as a clinical candidate. High as a pharmacological research tool.

Side-effect profile: Preclinical only. The N-benzyl phenethylamine series has produced compounds (25I-NBOMe, 25C-NBOMe) associated with toxicity and fatalities in recreational misuse, raising concerns about the therapeutic index of this structural class. 25CN-NBOH itself has not produced reports of severe toxicity in preclinical use, but the class association complicates the translational prospects.

Overall validation: Moderate. The compound is the principal selective 5-HT_{2A} agonist tool in preclinical research and has generated a substantial pharmacological literature. The absence of clinical development limits its validation as a therapeutic candidate.

Comparison to LPH-5: 25CN-NBOH and LPH-5 share comparable binding affinity and selectivity for the 5-HT_{2A} receptor but differ structurally (N-benzyl phenethylamine versus piperidine-restricted phenethylamine) and in development trajectory. LPH-5 is in clinical development with GLP-compliant toxicology; 25CN-NBOH is not. The piperidine scaffold of LPH-5 may confer superior drug-like properties and a more favorable safety profile than the N-benzyl scaffold.

12.3 DOI (2,5-dimethoxy-4-iodoamphetamine)

Mechanism: DOI is a potent 5-HT_{2A/2C} receptor agonist of the amphetamine class with K_i values of approximately 0.7 nM (5-HT_{2A}) and approximately 2.2 nM (5-HT_{2C}). It is non-selective between 5-HT_{2A} and 5-HT_{2C} [20].

Development trajectory: DOI has been used as a reference 5-HT_{2A/2C} agonist in pharmacological research for approximately 40 years. It has not been developed for clinical application and is used exclusively as a research tool.

Novelty: Low. The compound is a historical reference and does not represent a novel pharmacological concept.

Effect size: DOI produces robust antidepressant-like effects in rodent models (forced swim test, chronic unpredictable mild stress) and induces the head-twitch response as a 5-HT_{2A} agonist. Effect sizes in antidepressant models are comparable to psilocybin and LPH-5. One study reported that DOI's antidepressant-like effects were abolished in 5-HT_{2A} knockout mice, providing strong mechanistic evidence for the target [21].

Promising potential: Low. No clinical development pathway.

Side-effect profile: DOI is an amphetamine derivative with sympathomimetic properties. It activates both 5-HT_{2A} and 5-HT_{2C} receptors and has activity at adrenergic receptors. The non-selective profile and the amphetamine backbone make it unsuitable for clinical development.

Overall validation: High as a pharmacological tool; absent as a clinical candidate.

Comparison to LPH-5: DOI is more potent at the 5-HT_{2A} receptor (K_i 0.7 nM versus 1.3 nM) but lacks selectivity over 5-HT_{2C}. LPH-5 was designed to capture the antidepressant efficacy of 5-HT_{2A} agonism (demonstrated by DOI in preclinical models) while eliminating the 5-HT_{2C} and adrenergic off-target activity.

12.4 LSD (lysergic acid diethylamide)

Mechanism: LSD is a broad-spectrum serotonin receptor agonist with high affinity for 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C}, 5-HT_{1A}, and dopamine D₂ receptors. The binding affinity at 5-HT_{2A} is approximately 3 to 7 nM (K_i). The exceptionally long duration of action (8 to 12 hours) reflects slow dissociation kinetics from the 5-HT_{2A} receptor, stabilized by a "lid" formed by extracellular loop 2 over the LSD binding pose within the receptor [22].

Development trajectory: LSD is in clinical development for anxiety, treatment-resistant depression, and cluster headache. Multiple Phase 2 trials have been completed, with MindMed's MM-120 (LSD tartrate) as the most advanced program. MindMed reported positive Phase 2b results for generalized anxiety disorder in 2023 and is pursuing Phase 3 development [23].

Novelty: Low. LSD was first synthesized in 1938 and its psychoactive properties were discovered in 1943.

Effect size: Phase 2 clinical data show significant anxiolytic and antidepressant effect sizes. The long duration of action (8 to 12 hours) is considered a disadvantage in the clinical setting relative to psilocybin (4 to 6 hours) and potentially LPH-5, because it requires prolonged clinical supervision.

Promising potential: Moderate. Phase 3 development is underway for anxiety indications. The long duration and the broad receptor profile are clinical disadvantages relative to more selective, shorter-acting candidates.

Side-effect profile: Similar to psilocybin (psychedelic effects, nausea, headache, anxiety) but with longer duration. The 5-HT_{2B} agonism raises the same cardiac concern as psilocybin for repeated-dose paradigms. The dopamine D₂ activity distinguishes LSD from pure serotonergic psychedelics and may contribute to both therapeutic effects and adverse events.

Overall validation: High. Extensive clinical research history and Phase 2/3 data.

Comparison to LPH-5: LSD is non-selective and long-acting; LPH-5 is selective and predicted to be shorter-acting. LPH-5 has the selectivity advantage; LSD has the clinical evidence advantage. The two compounds are pharmacologically dissimilar despite sharing the 5-HT_{2A} agonist mechanism.

12.5 Tabernanthalog (TBG)

Mechanism: Tabernanthalog is a synthetic, non-hallucinogenic analog of ibogaine designed by Olson et al. at the University of California, Davis. It activates the 5-HT_{2A} receptor but with a distinct signaling bias (preferential activation of intracellular signaling pathways associated with neuroplasticity over those associated with psychedelic effects) [24]. TBG promotes dendritic arbor complexity and spine formation in cortical neurons in vitro and produces antidepressant-like and anti-addictive effects in rodents without inducing the head-twitch response.

Development trajectory: TBG is a preclinical-stage compound. Delix Therapeutics has advanced related non-hallucinogenic neuroplastogens into clinical development. TBG itself has not entered human trials.

Novelty: High. The concept of non-hallucinogenic neuroplastogens that activate 5-HT2A receptor-dependent neuroplasticity pathways without producing psychedelic effects is a novel and actively debated therapeutic concept.

Effect size: Robust in preclinical models of depression, addiction, and anxiety. The absence of the head-twitch response (the hallucinogenic correlate) is a defining feature. No human efficacy data exist.

Promising potential: Moderate to high as a conceptual class. Low for TBG specifically (not in clinical development). The broader non-hallucinogenic neuroplasto-gen class is in early clinical evaluation through Delix Therapeutics and other companies.

Side-effect profile: The absence of hallucinogenic effects is the principal advantage. Preclinical safety has been adequate. The theoretical concern is whether the dissociation of neuroplasticity from the psychedelic experience also dissociates the therapeutic effect, since some clinical frameworks hold that the subjective psychedelic experience is integral to the antidepressant response [25].

Overall validation: Low. Preclinical only. The fundamental question of whether non-hallucinogenic 5-HT2A agonists produce equivalent antidepressant effects to hallucinogenic 5-HT2A agonists in humans has not been resolved.

Comparison to LPH-5: TBG and LPH-5 represent diametrically opposed approaches to 5-HT2A agonist drug development. LPH-5 is a hallucinogenic partial agonist designed for psychedelic-assisted therapy; TBG is a non-hallucinogenic biased agonist designed to bypass the psychedelic experience entirely. LPH-5 has the advantage of clinical development, defined pharmacology, and alignment with the psychedelic-assisted therapy paradigm that has produced positive Phase 3 data for psilocybin. TBG has the advantage of a potentially more scalable therapeutic model (no requirement for supervised dosing sessions) if the non-hallucinogenic approach proves clinically effective.

12.6 Comparator summary

The five comparators occupy distinct positions in the 5-HT2A receptor agonist landscape. **Psilocybin** is the most clinically validated compound in the class, with two positive Phase 3 trials and a potential first FDA approval by 2027, but is non-selective and carries the 5-HT2B cardiac concern in repeated-dose applications. **25CN-NBOH** matches LPH-5 in selectivity and potency but is a research tool without clini-

cal development. **DOI** is the historical reference agonist that established the link between 5-HT_{2A} agonism and antidepressant effects but is non-selective and clinically undevelopable. **LSD** is in Phase 3 for anxiety but is non-selective, long-acting, and pharmacologically promiscuous. **Tabernanthalog** represents the non-hallucinogenic approach that bypasses the psychedelic experience but has not been clinically validated.

LPH-5 occupies a unique position among these comparators: it is the only compound that combines high subtype selectivity (5-HT_{2A} over 5-HT_{2B} and 5-HT_{2C}), defined single-enantiomer stereochemistry, a hallucinogenic pharmacological profile consistent with the psychedelic-assisted therapy paradigm, and active clinical development. The principal question is whether the selectivity advantage translates into clinically meaningful improvements in safety and tolerability relative to psilocybin, whose Phase 3 data have demonstrated that the non-selective profile is clinically acceptable in the supervised single-dose therapeutic paradigm. In repeated-dose paradigms (if such development is pursued for chronic indications), the 5-HT_{2B} selectivity of LPH-5 would become a more material advantage.

The development risk for LPH-5 is primarily in the early clinical stage: the compound has not yet demonstrated safety and tolerability in humans (Phase 1 ongoing), has not demonstrated efficacy in depressed patients, and is competing in a landscape where psilocybin may already be approved by the time LPH-5 completes Phase 2 development. The differentiation strategy depends on the selectivity, the defined chemistry, and the potential for improved tolerability in specific patient populations (those with cardiac risk factors, those sensitive to dysphoric responses, or those who require repeated dosing).

13. References

1. Marcher-Rorsted E, Jensen AA, Smits G, Frydenvang K, Kristensen JL. Discovery and structure-activity relationships of 2,5-dimethoxyphenylpiperidines as selective serotonin 5-HT_{2A} receptor agonists. *J Med Chem.* 2024;67(9):7224-7244.
2. Lophora ApS. Selective serotonin 5-HT_{2A} receptor agonists. US Patent Application 2021/0137908. Filed May 13, 2021.
3. Wikipedia. LPH-5 (drug). [https://en.wikipedia.org/wiki/LPH-5_\(drug\)](https://en.wikipedia.org/wiki/LPH-5_(drug)). Accessed May 2026.
4. Lophora ApS. Lophora completes preclinical development of LPH-5 for treatment-resistant depression. Press release, November 22, 2022.
5. Nichols DE. Psychedelics. *Pharmacol Rev.* 2016;68(2):264-355.
6. Marcher-Rorsted E, et al. The selective serotonin 5-HT_{2A} receptor agonist (S)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine (LPH-5) induces persistent and robust antidepressant-like effects in rodents. *ACS Pharmacol Transl Sci.* 2025;8(6):1791-1803.
7. Lophora ApS. Lophora receives approval from EMA to initiate Phase I clinical trial for LPH-5. Press release, September 17, 2024.
8. Lophora ApS. Lophora announces first subjects dosed in Phase 1 clinical trial of LPH-5. Press release, May 28, 2025.
9. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT_{2B} receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. *Circulation.* 2000;102(23):2836-2841.
10. Beckley Psytech. Beckley Psytech bolsters pipeline of next-generation psychedelic medicines with research collaboration and strengthening of relationship with Lophora ApS. Press release, May 10, 2022.
11. Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. *Nat Rev Neurosci.* 2020;21(11):611-624.

12. Jensen AA, McCorvy JD, Leth-Petersen S, et al. The selective 5-HT_{2A} receptor agonist 25CN-NBOH: structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH. *Biochem Pharmacol.* 2020;177:113979.
13. Heisler LK, Zhou L, Bajwa P, Hsu J, Bhatt SD. Serotonin 5-HT_{2C} receptors regulate anxiety-like behavior. *Genes Brain Behav.* 2007;6(5):491-496.
14. Lophora ApS. Science and pipeline: LPH-5, LPH-48, and drug design platform. <https://www.lophora.com/pipeline/>. Accessed May 2026.
15. Compass Pathways. Compass Pathways successfully achieves primary endpoint in second Phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression. Press release, February 2026.
16. MedChemExpress. LPH-5: 5-HT_{2A} receptor agonist. Product listing. <https://www.medchemexpress.com/lph-5.html>. Accessed May 2026.
17. Gukasyan N, Griffiths RR, Yaden DB, et al. Psychedelics, attenuation, and clinical wisdom: a review of antidepressant-psychedelic interactions. *Psychopharmacology (Berl)*. 2023;240(3):455-470.
18. Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. *Neuropharmacology*. 2011;61(3):364-381.
19. Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. *Eur Neuropsychopharmacol.* 2016;26(8):1327-1337.
20. Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT₂ involvement in the mechanism of action of hallucinogenic agents. *Life Sci.* 1984;35(25):2505-2511.
21. Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT_{2R} activation in mice. *Proc Natl Acad Sci USA*. 2021;118(17):e2022489118.
22. Wacker D, Wang S, McCorvy JD, et al. Crystal structure of an LSD-bound human serotonin receptor. *Cell*. 2017;168(3):377-389.
23. MindMed. MindMed announces positive Phase 2b results for MM-120 (LSD) in generalized anxiety disorder. Press release, 2023.

24. Olson DE, Cameron LP, Tombari RJ, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. *Nature*. 2021;589(7842):474-479.
25. Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. *ACS Pharmacol Transl Sci*. 2021;4(2):568-572.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. LPH-5 is an investigational compound that has not been approved by any regulatory authority for any therapeutic indication. The compound is in Phase 1 clinical evaluation; no human efficacy data have been published. All statements regarding therapeutic potential are based on preclinical data and on the clinical evidence for the broader class of 5-HT_{2A} receptor agonists. Investigators should consult their local regulatory authority before any research application. The compound is not explicitly scheduled in the United States but may be subject to analog legislation if intended for human consumption.